July 18 and September 6, 2022, Virtual Meeting
Nicola Gökbuget, MD
University Hospital Frankfurt, Germany
Dr Nicola Gökbuget has worked at the University Hospital Frankfurt, Germany, for more than 25 years and as senior physician she heads the study center of the Department of Medicine II. She is task force director for clinical trials of the University Cancer Center.
Dr Gökbuget is coordinating or principal investigator of numerous academic or industry-sponsored trials in adult acute lymphoblastic leukemia (ALL) and related diseases such as lymphoblastic lymphoma or Burkitt’s lymphoma. For more than 20 years, she has served as coordinator of the German Multicenter Study Group for ALL (GMALL) with more than 140 participating hospitals across Germany. She is the GMALL chair for adult ALL. She founded and established a national registry for ALL with an associated biobank, and has chaired the European Hematology Association Scientific Working Group for ALL for the past 3 years. Dr Gökbuget is a founding member and board member of the German Network for Acute and Chronic Leukemias and the European Leukemia Network (ELN). She is also a founding member of the ELN Working Group for Adult ALL and is editor of the European ALL guidelines book.
Nicolas Boissel, MD, PhD
Hôpital Saint-Louis, France
Dr Nicolas Boissel is head of the adolescent and young adults unit, Department of Hematology, Hôpital Saint-Louis in Paris, France, and professor of medicine at Université de Paris. After beginning his career as a research fellow at the Pasteur Institute and as an intern at Paris Municipal Hospitals, he completed a PhD at the Department of Immunology at Saint-Louis Hospital in 2002 while completing his MD at the Université de Paris. In 2005, he went on to become assistant professor at Hôpital Saint-Louis in the acute leukemia unit, before taking up his current position in 2010.
Dr Boissel is engaged in therapeutics for patients with bone marrow disorders, including acute leukemia, lymphoma, and aplastic anemia, with a specific focus on adolescent and young adult comprehensive care. His clinical research interests include the role of new oncogenic events and minimal residual disease to stratify therapeutic approaches in acute , as well as the development of immunotherapy in the field. He is involved in many trials designed to improve the outcome of acute leukemia patients. He is chairman of the Group for Research on Adult Acute Lymphoblastic Leukemia and of the French Onco-hematology Group for Adolescents and Young Adults (GO-AJA).